Published in Blood Weekly, January 27th, 2000
"Marrow cells are currently the most widely utilized target in human trials of gene therapies, and hematopoietic stem cells may be the best target of all," stated S. L. Kirby and colleagues from the University of North Carolina School of Medicine, North Carolina.
Kirby et al. published the results of their study in the journal Hospital Practice ("Bone Marrow: Target for Gene Transfer," Hospital Practice, December 15, 1999;34(13):59+).
According to the researchers, bone...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.